top of page

Mwandishi

Mhariri:

ULY CLINIC

Dkt. Benjamin L, MD

18 Machi 2021, 18:51:29

Trimethoprim na ujauzito

Trimethoprim na ujauzito

Trimethoprim inayofahamika kusababisha madhaifu ya kiuumbaji kwa vichanga kwa binadamu na wanyama. Madhaifu ya kiuumbaji kwa vichanga wanaozaliwa ambayo yamekuwa yakihusiana na matumizi ya dawa hii kwa wamama wajawazito ni pamoja na madhaofu ya moyo na mfumo wa fahamu pamoja na mdomo sungura. Matumizi ya Folic acid kiasi cha miligramu 0.4 kwa siku unatakiwa kufanyika kabla ya kushika mimba ili kuzuia kutokea kwa madhaifu hayo.


Ushauri dhidi ya matumizi kwa mama mjamzito


Taarifa za binadamu (wanyama) zinaonyesha hatari ya kupata madhara


Taarifa za binadamu (wanyama) zinaonyesha hatari ya kupata madhara, ina maana gani?

Taarifa za matumizi ya dawa hii au zile zilizo kundi moja na hii au zile zinazofanana namna zinavyofanya kazi na hii kwa binadamu na wanyama wajawazito , imeonekana kuwa sumu kwenye uumbaji wa kichanga tumboni kwa na kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo cha kichanga au kijusi tumboni katika kipindi chote cha ujauzito. Hata hivyo hatari inaweza kuvumiliwa endpo shida ya mama inahitaji dawa hii.


Ushauri wa matumizi kwa mama anayenyonyesha


Inapatana na unyonyeshaji


Inapatana na unyonyeshaji, ina maana gani?

Kiasi kidogo cha dawa hii kinawezekana kuingia kwenye maziwa ya mama, kiasi hiki hakina mashiko ya kusababisha sumu kwa kichanga anayenyonya. Dawa hii haitarajiwi kusababisha madhara kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii.

ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha  vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.

Imeboreshwa,

4 Juni 2025, 19:01:04

​

  1. McEwen LM. Trimethoprim/sulphamethoxazole mixture in pregnancy. Br Med J. 1971;4:490–1.

  2. Smithells RW. Co-trimoxazole in pregnancy. Lancet. 1983;2:1142.

  3. Tan JS, File TM Jr. Treatment of bacteriuria in pregnancy. Drugs. 1992;44:972–80.

  4. Williams JD, et al. The treatment of bacteriuria in pregnant women with sulphamethoxazole and trimethoprim. Postgrad Med J. 1969;45(Suppl):71–6.

  5. Ochoa AG. Trimethoprim and sulfamethoxazole in pregnancy. JAMA. 1971;217:1244.

  6. Brumfitt W, Pursell R. Double-blind trial to compare ampicillin, cephalexin, co-trimoxazole, and trimethoprim in treatment of urinary infection. Br Med J. 1972;2:673–6.

  7. Brumfitt W, Pursell R. Trimethoprim/sulfamethoxazole in the treatment of bacteriuria in women. J Infect Dis. 1973;128(Suppl):S657–63.

  8. Brumfitt W, Pursell R. Trimethoprim/sulfamethoxazole in the treatment of urinary infection. Med J Aust. 1973;1(Suppl):44–8.

  9. Bailey RR. Single-dose antibacterial treatment for bacteriuria in pregnancy. Drugs. 1984;27:183–6.

  10. Soper DE, Merrill-Nach S. Successful therapy of penicillinase-producing Neisseria gonorrhoeae pharyngeal infection during pregnancy. Obstet Gynecol. 1986;68:290–1.

  11. Cruikshank DP, Warenski JC. First-trimester maternal Listeria monocytogenes sepsis and chorioamnionitis with normal neonatal outcome. Obstet Gynecol. 1989;73:469–71.

  12. Seoud M, et al. Brucellosis in pregnancy. J Reprod Med. 1991;36:441–5.

  13. Frederiksen B. Maternal septicemia with Listeria monocytogenes in second trimester without infection of the fetus. Acta Obstet Gynecol Scand. 1992;71:313–5.

  14. Ronen GM. Holoprosencephaly and maternal low-calorie weight-reducing diet. Am J Med Genet. 1992;42:139.

  15. Richardson MP, et al. Spinal malformations in the fetuses of HIV infected women receiving combination antiretroviral therapy and co-trimoxazole. Eur J Obstet Gynecol Reprod Biol. 2000;93:215–7.

  16. Hernandez-Diaz S, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608–14.

  17. Hernandez-Diaz S, Mitchell AA. Folic acid antagonists during pregnancy and risk of birth defects. N Engl J Med. 2001;344:934–5.

  18. Hernandez-Diaz S, et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol. 2001;153:961–8.

  19. Shepard TH, et al. Update on new developments in the study of human teratogens. Teratology. 2002;65:153–61.

  20. Czeizel AE, et al. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol. 2001;15:637–46.

  21. Product information. Septra. Monarch Pharmaceuticals, 2001.

  22. Ylikorkala O, et al. Trimethoprim-sulfonamide combination administered orally and intravaginally in the 1st trimester of pregnancy: its absorption into serum and transfer to amniotic fluid. Acta Obstet Gynecol Scand. 1973;52:229–34.

  23. Reid DWJ, et al. Maternal and transplacental kinetics of trimethoprim and sulfamethoxazole, separately and in combination. Can Med Assoc J. 1975;112:67s–72s.

  24. Reeves DS, Wilkinson PJ. The pharmacokinetics of trimethoprim and trimethoprim/sulfonamide combinations, including penetration into body tissues. Infection. 1979;7(Suppl 4):S330–41.

  25. Bawdon RE, et al. Trimethoprim and sulfamethoxazole transfer in the in vitro perfused human cotyledon. Gynecol Obstet Invest. 1991;31:240–2.

  26. Koutras A, Fisher S. Niikawa-Kuroki syndrome: a new malformation syndrome of postnatal dwarfism, mental retardation, unusual face, and protruding ears. J Pediatr. 1982;101:417–9.

  27. Niikawa N, et al. Birth Defects Encyclopedia. Volume 2. Dover, MA: Center for Birth Defects Information Services; 1990. p. 998–9.

  28. Murdia A, et al. Sulpha-trimethoprim combinations and male fertility. Lancet. 1978;2:375–6.

  29. Grimmer SFM, et al. The effect of cotrimoxazole on oral contraceptive steroids in women. Contraception. 1983;28:53–9.

  30. Arnauld R, et al. A study of the passage of trimethoprim into the maternal milk. Quest Med. 1972;25:959–64.

  31. Miller RD, Salter AJ. The passage of trimethoprim/sulphamethoxazole into breast milk and its significance. In: Daikos GK, ed. Progress in Chemotherapy, Proceedings of the Eighth International Congress of Chemotherapy, Athens, 1973. Athens: Hellenic Society for Chemotherapy; 1974. p. 687–91.

  32. Ito S, et al. Prospective follow-up of adverse in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168:1393–9.

  33. Committee of Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.

bottom of page